Colgate-Palmolive (CL) Shares Sold by Transamerica Financial Advisors Inc.

Transamerica Financial Advisors Inc. lessened its stake in shares of Colgate-Palmolive (NYSE:CL) by 5.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,857 shares of the company’s stock after selling 1,612 shares during the quarter. Transamerica Financial Advisors Inc.’s holdings in Colgate-Palmolive were worth $1,854,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Advisor Group Inc. boosted its stake in Colgate-Palmolive by 24.5% during the 4th quarter. Advisor Group Inc. now owns 77,352 shares of the company’s stock valued at $5,838,000 after purchasing an additional 15,212 shares during the period. Summit Global Investments boosted its stake in Colgate-Palmolive by 27.8% during the 1st quarter. Summit Global Investments now owns 60,666 shares of the company’s stock valued at $4,348,000 after purchasing an additional 13,191 shares during the period. Steward Partners Investment Advisory LLC bought a new stake in Colgate-Palmolive during the 3rd quarter valued at approximately $2,509,000. Pratt Collard Advisory Partners LLC bought a new stake in Colgate-Palmolive during the 4th quarter valued at approximately $1,185,000. Finally, Gradient Investments LLC boosted its stake in Colgate-Palmolive by 6.5% during the 4th quarter. Gradient Investments LLC now owns 106,168 shares of the company’s stock valued at $8,010,000 after purchasing an additional 6,478 shares during the period. Institutional investors own 73.23% of the company’s stock.

In other news, insider Daniel B. Marsili sold 19,500 shares of the firm’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $71.85, for a total value of $1,401,075.00. Following the transaction, the insider now directly owns 77,935 shares in the company, valued at approximately $5,599,629.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Helene D. Gayle sold 7,000 shares of the firm’s stock in a transaction on Thursday, May 10th. The stock was sold at an average price of $62.23, for a total value of $435,610.00. Following the completion of the transaction, the director now owns 35,395 shares in the company, valued at $2,202,630.85. The disclosure for this sale can be found here. Insiders sold a total of 142,079 shares of company stock worth $8,981,683 over the last quarter. Corporate insiders own 1.02% of the company’s stock.

CL stock traded up $0.25 during midday trading on Thursday, reaching $63.31. 4,299,412 shares of the company’s stock traded hands, compared to its average volume of 4,272,681. The stock has a market capitalization of $55.61 billion, a price-to-earnings ratio of 22.06, a P/E/G ratio of 2.57 and a beta of 0.75. The company has a debt-to-equity ratio of 64.85, a current ratio of 1.08 and a quick ratio of 0.75. Colgate-Palmolive has a 1-year low of $61.28 and a 1-year high of $77.91.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, April 27th. The company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. The firm had revenue of $4 billion for the quarter, compared to analyst estimates of $4.01 billion. Colgate-Palmolive had a return on equity of 1,486.69% and a net margin of 13.30%. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period last year, the company earned $0.67 EPS. equities analysts expect that Colgate-Palmolive will post 3.15 earnings per share for the current fiscal year.

Several analysts recently weighed in on CL shares. Argus upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating in a research note on Friday, May 25th. They noted that the move was a valuation call. Morgan Stanley downgraded Colgate-Palmolive from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 30th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $75.00 price target on shares of Colgate-Palmolive in a report on Wednesday, April 18th. Zacks Investment Research raised Colgate-Palmolive from a “sell” rating to a “hold” rating in a report on Tuesday, April 17th. Finally, Barclays set a $70.00 price target on Colgate-Palmolive and gave the company a “hold” rating in a report on Monday, April 30th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $76.08.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply